Capricor's Challenges: FDA Review Delays and Legal Woes
Capricor Under the Spotlight: FDA and SEC Concerns Ah, Capricor Therapeutics, Inc. (NASDAQ: CAPR)—a tale of high stakes and even higher expectations now hanging by a very taut thread. Investors are feeling the heat as the U.S. Food and Drug Administration (FDA) presses pause on Capricor's plans, and the courtroom drama unfolds with a securities class action looming over...
Continue Reading